<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36726623</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>27</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2296-2565</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in public health</Title><ISOAbbreviation>Front Public Health</ISOAbbreviation></Journal><ArticleTitle>Clinical characteristics and related influencing factors of common rheumatic diseases concomitant with tuberculosis.</ArticleTitle><Pagination><StartPage>948652</StartPage><MedlinePgn>948652</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">948652</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fpubh.2022.948652</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To explore the clinical characteristics and risk factors of common systemic rheumatism concomitant with tuberculosis (TB).</AbstractText><AbstractText Label="METHODS">A total of 3,906 patients of RA, SLE, and SS diagnosed in the People's Hospital of Sichuan Province from January 2007 to January 2017 were collected. One hundred and five patients with TB were included as TB group, including 42 RA, 41 SLE, and 22 SS patients. In the non-TB group, 84 RA, 82 SLE, and 44 SS patients were randomly selected during the same period.</AbstractText><AbstractText Label="RESULTS">Fever was the most common symptom among RA, SLE, and SS patients with TB, accounting for 83.3%, 92.7%, and 68.2%, respectively. Cough, weight loss or fatigue were the next common. RA patients with TB were mostly pulmonary TB (PTB), accounting for 64.3%. The proportion of PTB for SLE and SS were 46.3%, 59.01%, respectively. In TB group, 59% RA, 57% SLE, and 62% SS with PTB had two or more chest CT findings. There were 48 TB cases received both Interferon Gamma Release Assay (IGRA) and Tuberculin skin test (TST) with positive rates of 91.8%, 45.8%, respectively. The daily average dose of glucocorticoids within 1 year in TB group was higher than that in non-TB group of SLE patients, lower counts of CD4+ T cell count were found in TB group (<i>P</i> &lt; 0.05), while no such differences were found in RA and SS patients.</AbstractText><AbstractText Label="CONCLUSION">RA patients with TB are mainly pulmonary TB. For SLE and SS patients, the chance of PTB and extrapulmonary tuberculosis is similar. Daily average dose of glucocorticoids within 1 year may be a common risk factor for RA, SLE and SS patients developing TB. Decreased CD4+ T cell count may also be a risk factor for SLE patients with TB. Symptoms of RA, SLE, SS with TB, are similar with the primary disease or other infection. It is recommended to conduct both TST and IGRA to help diagnose TB.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Tang, Chen, Han, Peng, Liu, Liu, Guo, Wu, Liu, Zhou and Long.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Guo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Bishan Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xixi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Yaxin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The People's Hospital of WenJiang, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Chengdu Second People's Hospital, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jiajun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nephrology and Rheumatology, The First Clinical Medical College, Zunyi Medical University, Zunyi, Guizhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nephrology and Rheumatology, The First Clinical Medical College, Zunyi Medical University, Zunyi, Guizhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Hongmei</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Clinical Medical College, University of Electronic Science and Technology of China, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xiaodan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Qiao</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Long</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Public Health</MedlineTA><NlmUniqueID>101616579</NlmUniqueID><ISSNLinking>2296-2565</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055985" MajorTopicYN="Y">Latent Tuberculosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014376" MajorTopicYN="Y">Tuberculosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059425" MajorTopicYN="N">Interferon-gamma Release Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012216" MajorTopicYN="Y">Rheumatic Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014397" MajorTopicYN="Y">Tuberculosis, Pulmonary</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">clinical characteristics</Keyword><Keyword MajorTopicYN="N">concomitant</Keyword><Keyword MajorTopicYN="N">interferon gamma release assay</Keyword><Keyword MajorTopicYN="N">rheumatic diseases</Keyword><Keyword MajorTopicYN="N">tuberculin skin test</Keyword><Keyword MajorTopicYN="N">tuberculosis</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>2</Day><Hour>1</Hour><Minute>59</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36726623</ArticleId><ArticleId IdType="pmc">PMC9884836</ArticleId><ArticleId IdType="doi">10.3389/fpubh.2022.948652</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. Global Tuberculosis Report 2021 (EB/OL). Available online at: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2021 (accessed October 14, 2021).</Citation></Reference><Reference><Citation>Long Q, Guo L, Jiang W, Huan S, Tang S. Ending tuberculosis in China: health system challenges. Lancet Public Health. (2021) 6:e948&#x2013;53. 10.1016/S2468-2667(21)00203-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-2667(21)00203-6</ArticleId><ArticleId IdType="pubmed">34838198</ArticleId></ArticleIdList></Reference><Reference><Citation>Su&#xe1;rez I, F&#xfc;nger SM, Kr&#xf6;ger S, Rademacher J, F&#xe4;tkenheuer G, Rybniker J. The diagnosis and treatment of tuberculosis. Dtsch Arztebl Int. (2019) 116:729&#x2013;35. 10.3238/arztebl.2019.0729</Citation><ArticleIdList><ArticleId IdType="doi">10.3238/arztebl.2019.0729</ArticleId><ArticleId IdType="pubmed">31755407</ArticleId></ArticleIdList></Reference><Reference><Citation>Anton C, Machado FD, Ramirez JMA, Bernardi RM, Palominos PE, Brenol CV, et al. . Latent tuberculosis infection in patients with rheumatic diseases. J Bras Pneumol. (2019) 45:e20190023. 10.1590/1806-3713/e20190023</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/1806-3713/e20190023</ArticleId><ArticleId IdType="pmc">PMC6733747</ArticleId><ArticleId IdType="pubmed">31038654</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao X, Da G, Xie X, Liu X, Zhang L, Zhou B, et al. . Tuberculosis in patients with systemic lupus erythematosus-a 37-year longitudinal survey-based study. J Intern Med. (2021) 290:101&#x2013;15. 10.1111/joim.13218</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.13218</ArticleId><ArticleId IdType="pubmed">33259665</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardam M, Iverson K. Rheumatoid arthritis and tuberculosis: time to take notice. J Rheumatol. (2003) 30:1397&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12858431</ArticleId></ArticleIdList></Reference><Reference><Citation>Miltiniene D, Deresevi&#x10d;iene G, Nak&#x10d;eriene B, Davidavi&#x10d;iene VE, Danila E, Butrimiene I, et al. . Incidence of tuberculosis in inflammatory rheumatic diseases: results from a Lithuanian retrospective cohort study. Medicina (Kaunas). (2020) 56:392. 10.3390/medicina56080392</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina56080392</ArticleId><ArticleId IdType="pmc">PMC7466317</ArticleId><ArticleId IdType="pubmed">32764422</ArticleId></ArticleIdList></Reference><Reference><Citation>Au K, Reed G, Curtis JR, Kremer JM, Greenberg JD, Strand V, et al. . High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis. (2011) 70:785&#x2013;91. 10.1136/ard.2010.128637</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2010.128637</ArticleId><ArticleId IdType="pubmed">21288960</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh JA, Hossain A, Kotb A, Wells G. Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis. BMC Med. (2016) 14:137. 10.1186/s12916-016-0673-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-016-0673-8</ArticleId><ArticleId IdType="pmc">PMC5022202</ArticleId><ArticleId IdType="pubmed">27623861</ArticleId></ArticleIdList></Reference><Reference><Citation>Duru N, van der Goes MC, Jacobs JW, Andrews T, Boers M, Buttgereit F, et al. . EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. (2013) 72:1905&#x2013;13. 10.1136/annrheumdis-2013-203249</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-203249</ArticleId><ArticleId IdType="pubmed">23873876</ArticleId></ArticleIdList></Reference><Reference><Citation>Walzl G, McNerney R, du Plessis N, Bates M, McHugh TD, Chegou NN, et al. . Tuberculosis: advances and challenges in development of new diagnostics and biomarkers. Lancet Infect Dis. (2018) 18:e199&#x2013;210. 10.1016/S1473-3099(18)30111-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(18)30111-7</ArticleId><ArticleId IdType="pubmed">29580818</ArticleId></ArticleIdList></Reference><Reference><Citation>Allwood BW, Byrne A, Meghji J, Rachow A, van der Zalm MM, Schoch OD. Post-tuberculosis lung disease: clinical review of an under-recognised global challenge. Respiration. (2021) 100:751&#x2013;63. 10.1159/000512531</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000512531</ArticleId><ArticleId IdType="pubmed">33401266</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Zhang L, Zhang F, Zeng X, Zhao Y, Wang Q, et al. . Prevalence and risk factors of active tuberculosis in patients with rheumatic diseases: a multi-center, cross-sectional study in China. Emerg Microbes Infect. (2021) 10:2303&#x2013;12. 10.1080/22221751.2021.2004864</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.2004864</ArticleId><ArticleId IdType="pmc">PMC8654396</ArticleId><ArticleId IdType="pubmed">34753408</ArticleId></ArticleIdList></Reference><Reference><Citation>Balbi GGM, Machado-Ribeiro F, Marques CDL, Signorelli F, Levy RA. The interplay between tuberculosis and systemic lupus erythematosus. Curr Opin Rheumatol. (2018) 30:395&#x2013;402. 10.1097/BOR.0000000000000493</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000493</ArticleId><ArticleId IdType="pubmed">29438163</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada T, Nakajima A, Inoue E, Tanaka E, Hara M, Tomatsu T, et al. . Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan. Ann Rheum Dis. (2006) 65:1661&#x2013;3. 10.1136/ard.2005.047274</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2005.047274</ArticleId><ArticleId IdType="pmc">PMC1798455</ArticleId><ArticleId IdType="pubmed">16837491</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang YS, Liu CJ, Ou SM, Hu YW, Chen TJ, Lee HT, et al. . Tuberculosis infection in primary Sj&#xf6;gren's syndrome: a nationwide population-based study. Clin Rheumatol. (2014) 33:377&#x2013;83. 10.1007/s10067-013-2408-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-013-2408-y</ArticleId><ArticleId IdType="pubmed">24170112</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao WC, Lin CH, Liao TL, Chen YM, Chen DY, Chen HH. Association between a history of mycobacterial infection and the risk of newly diagnosed Sj&#xf6;gren's syndrome: a nationwide, population-based case-control study. PLoS ONE. (2017) 12:e0176549. 10.1371/journal.pone.0176549</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0176549</ArticleId><ArticleId IdType="pmc">PMC5423582</ArticleId><ArticleId IdType="pubmed">28486537</ArticleId></ArticleIdList></Reference><Reference><Citation>de Vries MK, Arkema EV, Jonsson J, Bruchfeld J, Jacobsson LTH, Askling J, et al. . Tuberculosis risk in ankylosing spondylitis, other spondyloarthritis, and psoriatic arthritis in Sweden: a population-based cohort study. Arthritis Care Res (Hoboken). (2018) 70:1563&#x2013;7. 10.1002/acr.23487</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23487</ArticleId><ArticleId IdType="pubmed">29195024</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim CH, Chen HH, Chen YH, Chen DY, Huang WN, Tsai JJ, et al. . The risk of tuberculosis disease in rheumatoid arthritis patients on biologics and targeted therapy: a 15-year real world experience in Taiwan. PLoS ONE. (2017) 12:e0178035. 10.1371/journal.pone.0178035</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0178035</ArticleId><ArticleId IdType="pmc">PMC5453436</ArticleId><ArticleId IdType="pubmed">28570568</ArticleId></ArticleIdList></Reference><Reference><Citation>Kay J, Upchurch KS. ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford). (2012) 51 Suppl 6:vi5&#x2013;9. 10.1093/rheumatology/kes279</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kes279</ArticleId><ArticleId IdType="pubmed">23221588</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Orbai AM, Alarc&#xf3;n GS, Gordon C, Merrill JT, Fortin PR, et al. . Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. (2012) 64:2677&#x2013;86. 10.1002/art.34473</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34473</ArticleId><ArticleId IdType="pmc">PMC3409311</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. . Classification criteria for Sj&#xf6;gren&#x2032;s syndrome: a revised version of the European criteria proposed by the American-European ConsensusGroup. Ann Rheum Dis. (2002) 61:554&#x2013;8. 10.1136/ard.61.6.554</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.61.6.554</ArticleId><ArticleId IdType="pmc">PMC1754137</ArticleId><ArticleId IdType="pubmed">12006334</ArticleId></ArticleIdList></Reference><Reference><Citation>NHFPC . Classification of tuberculosis (WS196-2017). Chin J Infect Control. (2018) 17:368&#x2013;9. 10.3969/j.issn.1671-9638.2018.04.019</Citation><ArticleIdList><ArticleId IdType="doi">10.3969/j.issn.1671-9638.2018.04.019</ArticleId></ArticleIdList></Reference><Reference><Citation>NHFPC . Diagnosis for pulmonary tuberculosis (WS288-2017). Chin J Infect Control. (2018) 17:642&#x2013;52. 10.3969/j.issn.1671-9638.2018.07.019</Citation><ArticleIdList><ArticleId IdType="doi">10.3969/j.issn.1671-9638.2018.07.019</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Franco M, Lucchino B, Spaziante M, Iannuccelli C, Valesini G, Iaiani G. Lung infections in systemic rheumatic disease: focus on opportunistic infections. Int J Mol Sci. (2017) 18:293. 10.3390/ijms18020293</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18020293</ArticleId><ArticleId IdType="pmc">PMC5343829</ArticleId><ArticleId IdType="pubmed">28146077</ArticleId></ArticleIdList></Reference><Reference><Citation>Mak A, Cheung MW, Chiew HJ, Liu Y, Ho RC. Global trend of survival and damage of systemic lupus erythematosus: meta-analysis and meta-regression of observational studies from the 1950s to 2000s. Semin Arthritis Rheum. (2012) 41:830&#x2013;9. 10.1016/j.semarthrit.2011.11.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2011.11.002</ArticleId><ArticleId IdType="pubmed">22257558</ArticleId></ArticleIdList></Reference><Reference><Citation>Baronnet L, Barnetche T, Kahn V, Lacoin C, Richez C, Schaeverbeke T. Incidence of tuberculosis in patients with rheumatoid arthritis. A systematic literature review. Joint Bone Spine. (2011) 78:279&#x2013;84. 10.1016/j.jbspin.2010.12.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbspin.2010.12.004</ArticleId><ArticleId IdType="pubmed">21273108</ArticleId></ArticleIdList></Reference><Reference><Citation>Yun JE, Lee SW, Kim TH, Jun JB, Jung S, Bae SC, et al. . The incidence and clinical characteristics of Mycobacterium tuberculosis infection among systemic lupus erythematosus and rheumatoid arthritis patients in Korea. Clin Exp Rheumatol. (2002) 20:127&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">12051389</ArticleId></ArticleIdList></Reference><Reference><Citation>Jick SS, Lieberman ES, Rahman MU, Choi HK. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum. (2006) 55:19&#x2013;26. 10.1002/art.21705</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.21705</ArticleId><ArticleId IdType="pubmed">16463407</ArticleId></ArticleIdList></Reference><Reference><Citation>Macauley P, Rapp M, Park S, Lamikanra O, Sharma P, Marcelin M, et al. . Miliary tuberculosis presenting with meningitis in a patient treated with mycophenolate for lupus nephritis: challenges in diagnosis and review of the literature. J Investig Med High Impact Case Rep. (2018) 6:2324709618770226. 10.1177/2324709618770226</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2324709618770226</ArticleId><ArticleId IdType="pmc">PMC5912272</ArticleId><ArticleId IdType="pubmed">29707591</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooray S, Zhang H, Breen R, Carr-White G, Howard R, Cuadrado M, et al. . Cerebral tuberculosis in a patient with systemic lupus erythematosus following cyclophosphamide treatment: a case report. Lupus. (2018) 27:670&#x2013;5. 10.1177/0961203317722849</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203317722849</ArticleId><ArticleId IdType="pubmed">28764615</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam LS Li EK, Wong SM, Szeto CC. Risk factors and clinical features for tuberculosis among patients with systemic lupus erythematosus in Hong Kong. Scand J Rheumatol. (2002) 31:296&#x2013;300. 10.1080/030097402760375205</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/030097402760375205</ArticleId><ArticleId IdType="pubmed">12455821</ArticleId></ArticleIdList></Reference><Reference><Citation>Long W, Cai F, Wang X, Zheng N, Wu R. High risk of activation of latent tuberculosis infection in rheumatic disease patients. Infect Dis (Lond). (2020) 52:80&#x2013;6. 10.1080/23744235.2019.1682187</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2019.1682187</ArticleId><ArticleId IdType="pubmed">31656117</ArticleId></ArticleIdList></Reference><Reference><Citation>Arkema EV, Jonsson J, Baecklund E, Bruchfeld J, Feltelius N, Askling J, et al. . Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments? Ann Rheum Dis. (2015) 74:1212&#x2013;7. 10.1136/annrheumdis-2013-204960</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-204960</ArticleId><ArticleId IdType="pubmed">24608401</ArticleId></ArticleIdList></Reference><Reference><Citation>Gopalaswamy R, Shanmugam S, Mondal R, Subbian S. Of tuberculosis and non-tuberculous mycobacterial infections&#x2014;a comparative analysis of epidemiology, diagnosis and treatment. J Biomed Sci. (2020) 27:74. 10.1186/s12929-020-00667-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-020-00667-6</ArticleId><ArticleId IdType="pmc">PMC7297667</ArticleId><ArticleId IdType="pubmed">32552732</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HA, Yoo CD, Baek HJ, Lee EB, Ahn C, Han JS, et al. . Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population. Clin Exp Rheumatol. (1998) 16:9&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">9543555</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>